Can Repurposed Drugs Reverse Established Fibrosis? Evidence from Experimental and Clinical Studies
Can repurposed drugs reverse established fibrosis? This narrative mini-review examines experimental and clinical evidence on five drugs: metformin, simvastatin, losartan, pentoxifylline, and colchicine. It asks whether each study shows a lower matrix burden at the end of treatment, a decline from the burden present when treatment began, or a reduction that persists after drug clearance. An evidence table summarises 12 comparisons from 10 primary studies, documenting treatment timing, evidence of fibrosis at baseline, comparators, outcomes, and follow-up. Delayed metformin and simvastatin reduced final lung collagen burden in experimental models, while the clinical studies showed mixed or inconclusive histological results. None of the reviewed comparisons established that a reduction persisted after drug clearance. The review outlines how pretreatment measurements, concurrent controls, and post-treatment follow-up can help determine whether an intervention slows further matrix accumulation or produces durable regression of established fibrosis.
Authors
- Christiano Gondim Moreira (ORCID: https://orcid.org/0009-0001-6133-7403)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.5281/zenodo.24292316
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- preprint